Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Clofarabine
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2009-12-03

Last Posted Date: 2018-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 63

Registration Number: NCT01025154

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: MDS
Leukemia
CML
AML

Interventions: Drug: Cytarabine
Drug: Fludarabine

First Posted Date: 2009-11-25

Last Posted Date: 2016-03-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 151

Registration Number: NCT01019317

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Phase 2

Completed

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Methotrexate
Radiation: radiotherapy
Drug: Ara-C
Drug: Rituximab
Drug: BCNU
Other: APBSCT
Drug: Thiotepa

First Posted Date: 2009-11-11

Last Posted Date: 2017-08-23

Lead Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Target Recruit Count: 126

Registration Number: NCT01011920

Locations: 🇨🇭
IOSI - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇮🇹
A.O. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇩🇪
Uniklinik Freiburg, Freiburg, Germany

and more 20 locations

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Recurrent Childhood Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Plasma Cell Leukemia
Progression of Multiple Myeloma or Plasma Cell Leukemia
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Childhood Hodgkin Lymphoma
t(14;16)

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-11-05

Last Posted Date: 2019-06-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01008462

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Conditions: Leukemia

First Posted Date: 2009-11-01

Last Posted Date: 2014-01-10

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 180

Registration Number: NCT01005758

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: imatinib mesylate
Drug: methotrexate
Drug: methylprednisolone
Drug: pegaspargase
Drug: vincristine sulfate

First Posted Date: 2009-11-01

Last Posted Date: 2023-01-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01005914

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Dasatinib
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Daunorubicin
Drug: Dexamethasone
Drug: Cytarabine
Drug: Mitoxantrone

First Posted Date: 2009-10-30

Last Posted Date: 2015-05-29

Lead Sponsor: The Catholic University of Korea

Target Recruit Count: 51

Registration Number: NCT01004497

Locations: 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷
Yonsei University Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of

and more 5 locations

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lymphoma
B-Cell Non-Hodgkin Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bortezomib
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Rituximab
Drug: Vorinostat

First Posted Date: 2009-10-09

Last Posted Date: 2020-03-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00992446

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2009-09-10

Last Posted Date: 2013-08-26

Lead Sponsor: Cancer Research UK

Target Recruit Count: 150

Registration Number: NCT00974792

Locations: 🇬🇧
Nottingham City Hospital, Nottingham, England, United Kingdom

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Doxorubicin
Drug: PEG-asparaginase
Drug: Cytarabine
Drug: Methotrexate
Drug: Imatinib
Drug: Clofarabine
Drug: 6 Mercaptopurine

First Posted Date: 2009-09-09

Last Posted Date: 2017-03-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00973752

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy